🔎 Trials Near Me

Akèy › Kansè Poumon ki pa ti selil › Florid › Deltona

Etid klinik pou Kansè Poumon ki pa ti selil nan Deltona, FL

15 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Deltona (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Ap rekriteFaz 3
  • Mid Florida Hematology and Oncology Center ( Site 0018), Orange City · 4 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06312137

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Ap rekriteFaz 3
  • Alpha Clinical Research Centers LLC, Orange City · 4 mi lwen
  • Florida Cancer Specialists, Orange City · 4 mi lwen
  • Mid Florida Hematology and Oncology Center, Orange City · 4 mi lwen
  • ak 1 plis
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07222566

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Ap rekriteFaz 3
  • Mid Florida Hematology and Oncology Center, Orange City · 4 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06758401

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

Ap rekriteFaz 1/2
  • Mid Florida Hematology and Oncology Center, Orange City · 4 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07227298

Pan-tumor MRD Study

Ap rekriteEtid obsèvasyon
  • Mid Florida Cancer Centers, Orange City · 4 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2026 · NCT06605404

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Ap rekriteFaz 3
  • Mid Florida Hematology and Oncology Center, Orange City · 4 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06875310

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Ap rekriteFaz 2/3
  • Mid Florida Cancer Centers, Orange City · 4 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT06712316

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Ap rekriteFaz 3
  • Mid Florida Hematology and Oncology Center, Orange City · 4 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07195695

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Ap rekriteFaz 2/3
  • Local Institution - 007-926-B, Daytona Beach · 26 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT04613596

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

Ap rekriteFaz 3
  • Mid-Florida Hematology & Oncology Centers, P.A., Orange City · 4 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06899126

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

Ap rekriteFaz 3
  • Research Site, Orange City · 4 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT06350097

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Ap rekriteFaz 1/2
  • Mid Florida Hematology and Oncology Center, Orange City · 4 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Jul 29, 2026 · NCT04198766

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Ap rekriteFaz 2
  • Mid Florida Hematology and Oncology Center, Orange City · 4 mi lwen
Laj 18 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT06463665

Etid Kansè Poumon ki pa ti selil nan lòt vil

Lòt etid nan Deltona

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.